公开(公告)号：EP3407907A1

公开(公告)日：2018-12-05

申请号：EP17744960.0

申请日：2017-01-27

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： HELMS, Jill ,  DHAMDHERE, Girija ,  LIU, Bo ,  SMITH, Andrew A. ,  GOMEZ, Alan W.

IPC分类号： A61K38/17

CPC分类号： A61K38/18 ,  A61K9/107 ,  C07K14/475 ,  C12N5/0031 ,  C12N2501/415 ,  C12N2510/02

摘要： Provided herein are methods and culture systems for production of a biologically active Wnt polypeptide under a minimal serum condition. Also described herein include methods and culture systems for production of a biologically active Wnt polypeptide in a serum-free condition.

公开(公告)号：EP3196296B1

公开(公告)日：2018-11-21

申请号：EP17159696.8

申请日：2005-09-08

申请人： Wisconsin Alumni Research Foundation

发明人： THOMSON, James, A ,  LUDWIG, Tenneille

IPC分类号： C12N5/0735

CPC分类号： C12N5/0606 ,  C12N2500/12 ,  C12N2500/20 ,  C12N2500/25 ,  C12N2500/32 ,  C12N2500/33 ,  C12N2500/36 ,  C12N2500/38 ,  C12N2500/40 ,  C12N2500/44 ,  C12N2500/46 ,  C12N2500/90 ,  C12N2500/98 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/415 ,  C12N2501/845 ,  C12N2501/999 ,  C12N2533/52 ,  C12N2533/54

摘要： Previous methods for culturing human embryonic stem cells have required either fibroblast feeder cells or a medium, which has been exposed to fibroblast feeder cells in order to maintain the stem cells in an undifferentiated state. It has now been found that if high levels of fibroblast growth factor are used in a medium with gamma amino butyric acid, pipecholic acid, lithium and lipids, the stem cells will remain undifferentiated indefinitely through multiple passages, even without feeder cells or conditioned medium. A humanized matrix of human proteins can be used as a basement matrix to culture the cells. New lines of human embryonic stem cells made using these culture conditions, the medium and the matrix, will never have been exposed to animal cells, animal products, feeder cells or conditioned medium.

公开(公告)号：EP3401391A1

公开(公告)日：2018-11-14

申请号：EP18169827.5

申请日：2013-11-28

申请人： Takara Bio Europe AB

发明人： KÜPPERS-MUNTHER, Barbara ,  EDSBAGGE, Josefina

IPC分类号： C12N5/071

CPC分类号： C12N5/067 ,  C12N2501/06 ,  C12N2501/385 ,  C12N2501/405 ,  C12N2501/415 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/03 ,  C12N2506/45 ,  C12N2533/52 ,  C12N2533/54

摘要： The present invention relates to directed differentiation and maturation of hepatocyte-like cells. In particular, the present invention relates to exposure of hepatocyte-like cells to an activator of a retinoic acid responsive receptor, such as retinoic acid (RA), optionally in combination with an inhibitor of GSK-3 (Glycogen synthase kinase 3) or activator of Wnt signalling and/or with the overlay of the cells with one or more components characteristic of the mammalian extracellular matrix (matrix overlay). The present invention also relates to exposure of hepatocyte-like cells to an activator of a retinoic acid responsive receptor, such as retinoic acid (RA), optionally in combination with an inhibitor of a cycline dependent kinase (CDK) and/or with the overlay of the cells with one or more components characteristic of the mammalian extracellular matrix (matrix overlay). The hepatocyte-like cells obtained in accordance with the present invention show a phenotype which is more similar to that of primary hepatocytes than previously shown.

公开(公告)号：EP3400286A1

公开(公告)日：2018-11-14

申请号：EP17702699.4

申请日：2017-01-06

申请人： Massachusetts Institute Of Technology ,  The Brigham and Women's Hospital, Inc.

发明人： KARP, Jeffrey, Michael ,  LANGER, Robert, Samuel ,  YIN, Xiaolei

IPC分类号： C12N5/071

CPC分类号： C12N5/0678 ,  C12N5/0613 ,  C12N5/0679 ,  C12N2500/38 ,  C12N2500/62 ,  C12N2501/01 ,  C12N2501/065 ,  C12N2501/11 ,  C12N2501/119 ,  C12N2501/13 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/335 ,  C12N2501/395 ,  C12N2501/415 ,  C12N2501/42 ,  C12N2501/71 ,  C12N2501/72 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2502/23 ,  C12N2533/90 ,  G01N33/5008

摘要： A population of enteroendocrine cells (EEC) is obtained from a mammalian post-natal cell population, such as a population including post-natal stem cells, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK/ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator. Also, the insulin expression of a population of mammalian cells is increased by treating the population with a plurality of small molecules that increase the insulin expression.

公开(公告)号：EP3395942A1

公开(公告)日：2018-10-31

申请号：EP17168051.5

申请日：2017-04-25

申请人： IMBA-Institut für Molekulare Biotechnologie GmbH

发明人： KNOBLICH, Jürgen A. ,  BAGLEY, Joshua A.

IPC分类号： C12N5/071 ,  C12N5/079

CPC分类号： C12N5/0697 ,  C12N5/0618 ,  C12N2500/99 ,  C12N2501/115 ,  C12N2501/41 ,  C12N2501/415 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2533/54

摘要： The present invention relates to an in vitro method of producing a bi- or multi-differentiated tissue with at least two tissue types comprising the steps of developing a first tissue to a stage of differentiation of interest, developing a second tissue to a stage of differentiation of interest differing from the stage of differentiation of interest of the first tissue, placing said first and second tissue in a vicinity sufficient for fusion by growth, allowing the first and second tissue to grow and fuse to each other, thereby producing a bi- or multi-differentiated tissue comprising the first and second tissue with different stages of differentiation ; bi- or multi-differentiated tissue obtained by such a method; uses of the tissue and kits for performing the method.

公开(公告)号：EP2942392B1

公开(公告)日：2018-10-03

申请号：EP15171064.7

申请日：2009-06-30

申请人： Janssen Biotech, Inc.

发明人： LIU, Jiajian ,  DAVIS, Janet ,  PARMENTER, Christine ,  BONNET, Pascal Ghislain André

IPC分类号： C12N5/0735 ,  C12N5/071

CPC分类号： C12N5/0606 ,  C12N5/0676 ,  C12N5/0678 ,  C12N2500/25 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/135 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/19 ,  C12N2501/385 ,  C12N2501/41 ,  C12N2501/415 ,  C12N2501/42 ,  C12N2501/727 ,  C12N2501/845 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2531/00 ,  C12N2533/50 ,  C12N2533/90

摘要： The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.

公开(公告)号：EP3371301A1

公开(公告)日：2018-09-12

申请号：EP16862624.0

申请日：2016-07-26

申请人： Fate Therapeutics, Inc.

发明人： VALAMEHR, Bahram ,  CLARKE, Raedun ,  BJORDAHL, Ryan

IPC分类号： C12N5/0789 ,  A61K35/28 ,  G01N33/569

CPC分类号： C12N5/0647 ,  A61K35/28 ,  A61K35/545 ,  A61K39/0011 ,  A61K2039/5158 ,  C12N2501/115 ,  C12N2501/155 ,  C12N2501/2302 ,  C12N2501/415 ,  C12N2501/727 ,  C12N2506/45 ,  G01N33/5073 ,  Y02A50/467

摘要： The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.

公开(公告)号：EP3371300A1

公开(公告)日：2018-09-12

申请号：EP16794570.8

申请日：2016-11-07

申请人： Centro en Investigación Biomédica en Red ,  Centro de Investigaciones Energéticas Medioambientales y Tecnologicas (CIEMAT) ,  Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz ,  Cellectis

发明人： SEGOVIA SANZ, José Carlos ,  QUINTANA BUSTAMANTE, Oscar ,  GÁRATE MUTILOA, Zita Maite ,  BUEREN RONCERO, Juan Antonio ,  DAVIS, Brian R. ,  GOUBLE, Agnes ,  GALETTO, Roman ,  POIROT, Laurent

IPC分类号： C12N5/0789 ,  C12N5/074

CPC分类号： C12N5/0647 ,  C12N5/0696 ,  C12N2500/25 ,  C12N2501/105 ,  C12N2501/113 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2311 ,  C12N2501/26 ,  C12N2501/415 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2501/727 ,  C12N2501/91 ,  C12N2506/11 ,  C12N2506/45 ,  C12N2510/00

摘要： The present invention relates to the medical field, in particular to gene editing as a therapeutic approach for the treatment of metabolic diseases affecting the erythroid lineage in a mammalian subject. In invention particular embodiment it refers to the combination of cell reprograming and gene editing for PKD correction as a first example of the potential application of these advanced technologies to metabolic diseases affecting the erythroid lineage. In this sense, PKD patient-specific iPSCs were efficiently generated from PB-MNCs (peripheral blood mononuclear cells) by a SeV non-integrative system and efficiently use to treat pyruvate kinase deficiency. The gene editing strategy for PKLR gene correction was also successfully applied directly to hematopoietic progenitors.

公开(公告)号：EP3365428A1

公开(公告)日：2018-08-29

申请号：EP16858294.8

申请日：2016-10-21

申请人： Indiana University Research & Technology Corporation

发明人： KOEHLER, Karl, R. ,  HASHINO, Eri

IPC分类号： C12N5/02 ,  C12N5/0793 ,  C12N5/0797 ,  C12N5/22

CPC分类号： C12N5/062 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/415 ,  C12N2506/02 ,  C12N2533/52 ,  C12N2533/90

摘要： Provided herein are methods for directing differentiation of human pluripotent stem cells into inner ear sensory epithelia and sensory neurons. More particularly, provided herein are methods for obtaining three-dimensional cultures comprising human pluripotent stem cell- derived pre-otic epithelium, otic vesicles, and inner ear sensory epithelia containing hair cells, sensory neurons, and supporting cells.

公开(公告)号：EP2401363B1

公开(公告)日：2018-08-22

申请号：EP10710685.8

申请日：2010-02-25

申请人： Tel HaShomer Medical Research Infrastructure and Services Ltd.

发明人： DEKEL, Benjamin ,  HARARI-STEINBERG, Orit

IPC分类号： C12N5/074

CPC分类号： A61K35/22 ,  C12N5/0686 ,  C12N5/0687 ,  C12N5/0696 ,  C12N15/85 ,  C12N2500/90 ,  C12N2501/06 ,  C12N2501/065 ,  C12N2501/415 ,  C12N2506/25

摘要： Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells.